Expert Interview
What to Expect from Phase 2 Data Evaluating Bellerophon's (BLPH) INOpulse Delivery Device for Pulmonary Hypertension Associated with COPD and Idiopathic Pulmonary Fibrosis Due in Q1 2017
Ticker(s): BLPHA cardiologist or other specialist who has experience treating patients with pulmonary arterial hypertension. He or she should be familiar with the INOpulse delivery device, and other devices used in treatment.
Can you describe your experience treating patients with pulmonary arterial hypertension, and your familiarity with the INOpulse delivery device?
Added By: pjloriaWhat other devices were used in this trial, and what devices are currently being used in treatment?
Added By: pjloriaHow do these devices compare to the INOpulse delivery device?
Added By: pjloriaWhat are important things to look for in the Phase 2 data release expected in early 2017? What are your expectations for this data release?
Added By: pjloriaGiven your current knowledge, what are your thoughts on the chances of approval and market potential for INOpulse in pulmonary hypertension?
Added By: pjloriaAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
